JPWO2021030240A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021030240A5 JPWO2021030240A5 JP2022508480A JP2022508480A JPWO2021030240A5 JP WO2021030240 A5 JPWO2021030240 A5 JP WO2021030240A5 JP 2022508480 A JP2022508480 A JP 2022508480A JP 2022508480 A JP2022508480 A JP 2022508480A JP WO2021030240 A5 JPWO2021030240 A5 JP WO2021030240A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- subject
- cancer
- amino acid
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962886270P | 2019-08-13 | 2019-08-13 | |
| US62/886,270 | 2019-08-13 | ||
| PCT/US2020/045567 WO2021030240A1 (en) | 2019-08-13 | 2020-08-10 | Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022544227A JP2022544227A (ja) | 2022-10-17 |
| JPWO2021030240A5 true JPWO2021030240A5 (zh) | 2023-08-16 |
Family
ID=74569853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022508480A Pending JP2022544227A (ja) | 2019-08-13 | 2020-08-10 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）による癌の治療方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230001005A1 (zh) |
| EP (1) | EP4013795A4 (zh) |
| JP (1) | JP2022544227A (zh) |
| KR (1) | KR20220054321A (zh) |
| CN (1) | CN114901690A (zh) |
| AU (1) | AU2020329761A1 (zh) |
| BR (1) | BR112022002391A2 (zh) |
| CA (1) | CA3150274A1 (zh) |
| IL (1) | IL290391A (zh) |
| MX (1) | MX2022001731A (zh) |
| TW (1) | TW202120557A (zh) |
| WO (1) | WO2021030240A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4143344A1 (en) * | 2020-04-27 | 2023-03-08 | Agendia N.V. | Treatment of her2 negative, mammaprint high risk 2 breast cancer |
| WO2024012536A1 (zh) * | 2022-07-14 | 2024-01-18 | 百奥泰生物制药股份有限公司 | 抗Nectin-4抗体、其抗体药物偶联物及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE038908T2 (hu) * | 2010-09-29 | 2018-12-28 | Agensys Inc | 191P4D12 proteinekhez kötõdõ antitest-gyógyszerkonjugátumok (ADC) |
| EP3303399A1 (en) * | 2015-06-08 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Methods of treating cancer using anti-ox40 antibodies |
| AR117652A1 (es) * | 2018-12-03 | 2021-08-25 | Agensys Inc | Composiciones farmacéuticas que comprenden conjugados de anticuerpo anti-191p4d12 y fármaco y métodos de usarlas |
-
2020
- 2020-08-10 BR BR112022002391A patent/BR112022002391A2/pt unknown
- 2020-08-10 WO PCT/US2020/045567 patent/WO2021030240A1/en unknown
- 2020-08-10 TW TW109127017A patent/TW202120557A/zh unknown
- 2020-08-10 KR KR1020227007845A patent/KR20220054321A/ko unknown
- 2020-08-10 US US17/634,026 patent/US20230001005A1/en active Pending
- 2020-08-10 CA CA3150274A patent/CA3150274A1/en active Pending
- 2020-08-10 EP EP20853452.9A patent/EP4013795A4/en active Pending
- 2020-08-10 JP JP2022508480A patent/JP2022544227A/ja active Pending
- 2020-08-10 AU AU2020329761A patent/AU2020329761A1/en active Pending
- 2020-08-10 CN CN202080071695.6A patent/CN114901690A/zh active Pending
- 2020-08-10 MX MX2022001731A patent/MX2022001731A/es unknown
-
2022
- 2022-02-07 IL IL290391A patent/IL290391A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021059564A (ja) | 癌治療のための併用療法 | |
| CN111065411A (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| US11325980B2 (en) | Combination therapy using a LIV1-ADC and a chemotherapeutic | |
| JP2020519675A5 (zh) | ||
| JP2021501776A5 (zh) | ||
| JP2021073203A (ja) | Ｈｅｒ２陽性転移性乳癌の治療方法 | |
| US20150010498A1 (en) | Immunocytokines for Cancer Treatment in Combination with Chemotherapeutic Agents | |
| JP2023533111A (ja) | 免疫チェックポイント阻害剤とのｓｔｉｎｇアゴニスト併用治療 | |
| CN115867317A (zh) | 用于治疗胰腺癌和其他实体瘤的方法 | |
| JPWO2021030240A5 (zh) | ||
| JPWO2019197506A5 (zh) | ||
| CN111973747A (zh) | 用于联合治疗卵巢癌的喹啉衍生物 | |
| WO2022002153A1 (zh) | 用于治疗肿瘤的药物 | |
| JPWO2018213260A5 (zh) | ||
| Vora et al. | Novel therapeutics in breast cancer—Looking to the future | |
| JPWO2019173523A5 (zh) | ||
| JPWO2019143607A5 (zh) | ||
| TW202045175A (zh) | Ｓｕｍｏ-活化酶抑制劑及檢查點抑制劑之投與 | |
| JPWO2019217457A5 (zh) | ||
| JPWO2019183253A5 (zh) | ||
| WO2023134706A1 (zh) | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 | |
| JPWO2019217455A5 (zh) | ||
| RU2024114358A (ru) | Способы лечения рака комбинацией антитела против pd-1 и конъюгата антитела против cd30-лекарственного средства | |
| Teicher | Antibody drug and radionuclide conjugates for GI cancers | |
| RU2023134007A (ru) | Применение конъюгата антитело-лекарственное средство в комбинации с ингибитором иммунных контрольных точек в лечении уротелиального рака |